The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function

被引:127
作者
Meisner, M
Lohs, T
Huettemann, E
Schmidt, J
Hueller, M
Reinhart, K
机构
[1] Univ Jena, Dept Anaesthesiol & Intens Care Therapy, D-07743 Jena, Germany
[2] Univ Erlangen Nurnberg, Dept Anaesthesiol & Intens Care Therapy, Erlangen, Germany
[3] Univ Jena, Inst Clin Chem & Lab Diagnost, D-6900 Jena, Germany
关键词
kidney failure; infection; septicaemia; pharmacokinetics; procalcitonin;
D O I
10.1046/j.0265-0215.2000.00783.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background and objective The amount of procalcitonin eliminated in the urine and the plasma disappearance rate of procalcitonin were evaluated in patients with normal and impaired renal function, because patients with sepsis are a main target group for procalcitonin measurement, and these patients often develop renal dysfunction. Methods Elimination of procalcitonin in the urine (mug 12 h(-1)) was measured in 76 patients. In another 67 patients, the 50% plasma disappearance rate (t 1/2, h) was evaluated 48 h after peak concentrations (procalcitonin >2 mug L-1). Renal function was assessed by creatinine clearance. Results Procalcitonin elimination in the urine was significantly reduced in patients with severe renal dysfunction. However, the plasma disappearance rate correlated only weakly with renal dysfunction (Spearman's rank correlation R=-0.36, P=0.004, regression t 1/2 = 49.87-0.15 creatinine clearance). The 25% quartile and median were 25.2 h and 30.0 h in patients with normal renal function, and 36.3 h and 44.7 h in patients with severely impaired renal function (creatinine clearance <30 mt min(-1)). Conclusions Renal elimination of procalcitonin is not a major mechanism for procalcitonin removal from the plasma. Although the plasma disappearance rate may be prolonged up to 30-50% in some patients with renal dysfunction, clinical diagnostic decisions may not be severely influenced by this moderate prolongation of procalcitonin elimination. We conclude that procalcitonin can be used diagnostically in patients with renal failure as well as in those with normal renal function.
引用
收藏
页码:79 / 87
页数:9
相关论文
共 21 条
  • [1] [Anonymous], 1999, J LAB MED
  • [2] Kinetics of procalcitonin in iatrogenic sepsis
    Brunkhorst, FM
    Heinz, U
    Forycki, ZF
    [J]. INTENSIVE CARE MEDICINE, 1998, 24 (08) : 888 - 889
  • [3] BRUNKHORST FM, 1996, CLIN INTENSIVE CARE, V7, P41
  • [4] PROCALCITONIN INCREASE AFTER ENDOTOXIN INJECTION IN NORMAL SUBJECTS
    DANDONA, P
    NIX, D
    WILSON, MF
    ALJADA, A
    LOVE, J
    ASSICOT, M
    BOHUON, C
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (06) : 1605 - 1608
  • [5] LEONARD P, 1995, TELECOMMUNICATIONS L, V3, P56
  • [6] Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS
    Meisner, M
    Tschaikowsky, K
    Palmaers, T
    Schmidt, J
    [J]. CRITICAL CARE, 1999, 3 (01): : 45 - 50
  • [7] Meisner M, 1997, EUR J CLIN CHEM CLIN, V35, P597
  • [8] The natural elimination rate of procalcitonin in patients with normal and impaired renal function
    Meisner, M
    Schmidt, J
    Hüttner, H
    Tschaikowsky, K
    [J]. INTENSIVE CARE MEDICINE, 2000, 26 : S212 - S216
  • [9] Elimination of procalcitonin and plasma concentrations during continuous veno-venous haemodiafiltration in septic patients
    Meisner, M
    Hüttemann, E
    Lohs, T
    Kasakov, L
    Reinhart, K
    [J]. EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 2000, 17 (11) : 665 - 671
  • [10] MEISNER M, 1999, INTENSIVE CARE ME S1, V25, P76